Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03178201 · ClinicalTrials.gov registry record · Phase 2
TGR1202 in Relapsed and Refractory Follicular Lymphoma
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03178201 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 5 participants.
The verdict
NCT03178201, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective is to determine the overall response rate (ORR) of TGR-1202 in R/R FL. Secondary Objectives * Determine the genetic and other novel biological markers that may be predictive of response or resistance to TGR-1202 in patients with relapsed or refractory FL. * Describe the Progression Free Survival (PFS), Duration of Response (DoR) after treatment with TGR-1202. * Describe the number of dose delays and dose reductions and other safety profile.
Interventions
- DRUG TGR-1202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-08-20 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03178201
The ClinicalTrials.gov registry entry for NCT03178201 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TGR-1202 is the first listed.
NCT03178201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03178201 about?
NCT03178201 is a clinical study titled "TGR1202 in Relapsed and Refractory Follicular Lymphoma". The primary objective is to determine the overall response rate (ORR) of TGR-1202 in R/R FL. Secondary Objectives * Determine the genetic and other novel biological markers that may be predictive of response or resistance to TGR-1202 in patients with relapsed or refractory FL. * Describe the Progr...
What is the current status of trial NCT03178201?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-08-20. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03178201?
The interventions under investigation include: TGR-1202 (DRUG).
Who is sponsoring clinical trial NCT03178201?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.